• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Hyoscyamine
    Information
    CAS No. 101-31-5 Price $40 / 20mg
    Catalog No.CFN00232Purity>=98%
    Molecular Weight289.37Type of CompoundAlkaloids
    FormulaC17H23NO3Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $11.8 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • Gyeongsang National University (Korea)
  • Cornell University (USA)
  • Fraunhofer-Institut für Moleku... (Germany)
  • Wageningen University (Netherlands)
  • Sant Gadge Baba Amravati Univer... (India)
  • University of the Basque Country (Spain)
  • Subang Jaya Medical Centre (Malaysia)
  • Seoul National University (Korea)
  • University of Illinois (USA)
  • Cancer Research Initatives Foun... (Malaysia)
  • Ain Shams University (Egypt)
  • More...
  • Package
    Featured Products
    Sibiricose A5

    Catalog No: CFN90645
    CAS No: 107912-97-0
    Price: $138/20mg
    Ginsenoside Rk3

    Catalog No: CFN92593
    CAS No: 364779-15-7
    Price: $180/10mg
    Leachianone A

    Catalog No: CFN97560
    CAS No: 97938-31-3
    Price: $358/10mg
    Kurarinone

    Catalog No: CFN92003
    CAS No: 34981-26-5
    Price: $118/20mg
    Curzerenone

    Catalog No: CFN92027
    CAS No: 20493-56-5
    Price: $258/10mg
    Tangeretin

    Catalog No: CFN90240
    CAS No: 481-53-8
    Price: $40/20mg
    Niranthin

    Catalog No: CFN98798
    CAS No: 50656-77-4
    Price: $453/5mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Anti-spasmodic Compound Library
  • Anticholinesterase Compound Library
  • Alkaloids Compound Library
  • AChR Inhibitor Library
  • Biological Activity
    Description: Hyoscyamine is an AChR inhibitor with IC50 of 7.5 nM, it is widely used in medicine due to its anticholinergic activity. Hyoscyamine could be used to reduce abdominal discomfort and colonic spasm during a barium enema.
    Targets: AChR
    In vivo:
    AJR Am J Roentgenol. 1993 Nov;161(5):965-8.
    Antispasmodic drugs to reduce discomfort and colonic spasm during barium enemas: comparison of oral hyoscyamine, i.v. glucagon, and no drug.[Pubmed: 8273637]
    Parenterally administered glucagon is currently the agent of choice for reducing abdominal discomfort and colonic spasm during a barium enema. Because glucagon is expensive and frequently causes nausea, we evaluated the use of oral Hyoscyamine sulfate as an alternate agent and compared it with IV glucagon and no medication.
    METHODS AND RESULTS:
    A total of 349 adult patients undergoing barium enema examinations were randomly assigned in a prospective fashion to one of four groups: (1) no medication (87 patients); (2) 1 mg of IV glucagon (88 patients); (3) 0.125 mg of oral Hyoscyamine sulfate (87 patients); and (4) 0.25 mg of oral Hyoscyamine sulfate (87 patients). The degree of distension of the colon on radiographs obtained after fluoroscopy, the amount of abdominal distress after the procedure, and the number of side effects (nausea, palpitations, blurred vision, dry mouth) were analyzed. To evaluate the amount of abdominal discomfort more completely, we asked the last 248 patients to estimate the level of severity of the discomfort (none, mild, moderate, or severe). We found no difference in the degree of distension of the colon in the four groups (p = .63). Most patients (79%) had some degree of abdominal discomfort. Fewer patients in the group who received no medication (10%) had no or mild pain compared with those given glucagon (15%, p < .05), 0.125 mg of Hyoscyamine (14%, p < .05), or 0.25 mg of Hyoscyamine (12%, p = .15). Less nausea occurred in the group that received 0.125 mg of Hyoscyamine than in the other groups (p < .03). No patients in any of the groups had allergic or severe side effects.
    CONCLUSIONS:
    When compared with IV glucagon, oral Hyoscyamine had fewer side effects, but the degree of colonic distension or abdominal distress was not significantly different. In addition, Hyoscyamine is considerably less expensive than glucagon and can be given orally. Patients who received medications had less discomfort than those who did not. However, the degree of distension was not different.
    J Community Support Oncol. 2015 Jan;13(1):3-7.
    Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome.[Pubmed: 25839059]
    Cholinergic syndrome is a well established acute adverse reaction associated with irinotecan. Cholinergic side effects can be ameliorated or prevented with anticholinergic agents. To date, no formal studies have compared atropine-diphenoxylate and Hyoscyamine as premedications for prophylaxis of the cholinergic syndrome with irinotecan infusion. To compare the incidence of cholinergic syndrome with irinotecan using atropine-diphenoxylate or Hyoscyamine as premedication.
    METHODS AND RESULTS:
    We conducted a retrospective, single-center, nonrandomized, cohort study of adult patients treated with atropine-diphenoxylate or Hyoscyamine as premedication before receiving irinotecan. For all irinotecan infusions, intravenous atropine was administered for patients experiencing any cholinergic reaction. A total of 532 irinotecan cycles (354 cycles for atropine-diphenoxylate group; 178 cycles for Hyoscyamine group) were analyzed in 80 patients. Overall incidence of cholinergic syndrome did not differ between atropine-diphenoxylate (8.2%) and Hyoscyamine (9.0%) groups (P = .76). The incidence of cholinergic syndrome after the £rst cycle of irinotecan was similar between the 2 arms, atropine-diphenoxylate (14.6%) and Hyoscyamine (10.7%), with P = .74. The most common cholinergic symptoms documented were abdominal pain or cramping, and diarrhea. This study was subjected to vulnerabilities to bias and random error because of its observational retrospective design and small number of participants.
    CONCLUSIONS:
    Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropinediphenoxylate and Hyoscyamine may both be effective prophylactic options. The findings support the need for a larger, randomized study to assess and compare these agents with other potential premedications such as scopolamine and atropine in prevention of irinotecan-related cholinergic syndrome.
    Hyoscyamine Description
    Source: The roots of Anisodus tanguticus
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Ganoderic acid G

    Catalog No: CFN90801
    CAS No: 98665-22-6
    Price: $400/10mg
    Eudesmin

    Catalog No: CFN96266
    CAS No: 526-06-7
    Price: $188/20mg
    Parishin A

    Catalog No: CFN93112
    CAS No: 62499-28-9
    Price: $120/20mg
    Cassiaside C

    Catalog No: CFN95120
    CAS No: 119170-52-4
    Price: $318/10mg
    Afzelin

    Catalog No: CFN98757
    CAS No: 482-39-3
    Price: $288/20mg
    Sagittatoside B

    Catalog No: CFN90211
    CAS No: 118525-36-3
    Price: $318/5mg
    Militarine

    Catalog No: CFN90409
    CAS No: 58139-23-4
    Price: $188/10mg
    3'-Hydroxymirificin

    Catalog No: CFN95102
    CAS No: 168035-02-7
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.4558 mL 17.2789 mL 34.5578 mL 69.1157 mL 86.3946 mL
    5 mM 0.6912 mL 3.4558 mL 6.9116 mL 13.8231 mL 17.2789 mL
    10 mM 0.3456 mL 1.7279 mL 3.4558 mL 6.9116 mL 8.6395 mL
    50 mM 0.0691 mL 0.3456 mL 0.6912 mL 1.3823 mL 1.7279 mL
    100 mM 0.0346 mL 0.1728 mL 0.3456 mL 0.6912 mL 0.8639 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Structure Identification:
    Phytochem Anal. 2014 Jan-Feb;25(1):29-35.
    Multi-development-HPTLC method for quantitation of hyoscyamine, scopolamine and their biosynthetic precursors in selected solanaceae plants grown in natural conditions and as in vitro cultures.[Pubmed: 23839972]
    Hyoscyamine and scopolamine, anti-cholinergic agents widely used in medicine, are typically obtained from plants grown under natural conditions. Since field cultivation entails certain difficulties (changeable weather, pests, etc.), attempts have been made to develop a plant in vitro culture system as an alternative source for the production of these compounds. During experiments to locate the limiting steps in the biotechnological procedure, it is important to monitor not only the levels of the final products but also the changes in the concentration of their precursors. To develop a HPTLC method for the separation and quantitation of the main tropane alkaloids Hyoscyamine and scopolamine, their respective direct precursors littorine and anisodamine, and cuscohygrine, a product of a parallel biosynthetic pathway that shares a common precursor (N-methyl-∆(1) -pyrrolium cation) with tropane alkaloids.
    METHODS AND RESULTS:
    Using alkaloid extracts from Atropa baetica hairy roots, different TLC chromatographic systems and developing procedures were investigated. Full separation of all compounds was obtained on HPTLC Si60 F254 plates preconditioned with mobile phase vapours (chloroform:methanol:acetone:25% ammonia ratios of 75:15:10:1.8, v/v/v/v). The chromatograms were developed twice (at distances of 4.0 and 3.0 cm) in a Camag twin trough chamber and visualised with Dragendorff's reagent. Densitometric detection (λ = 190 and 520 nm) was used for quantitative analyses of the different plant samples.
    CONCLUSIONS:
    This method can be recommended for quantitation of Hyoscyamine, scopolamine, anisodamine, littorine and cuscohygrine in different plant material (field grown vs. in vitro cultures).
    Microb Cell Fact. 2008 May 27;7:17.
    Expression of Brugmansia candida Hyoscyamine 6beta-Hydroxylase gene in Saccharomyces cerevisiae and its potential use as biocatalyst.[Pubmed: 18505565 ]
    Tropane alkaloids, mainly Hyoscyamine and scopolamine, are widely used in medicine due to their anticholinergic activity. Scopolamine has a higher demand being the more valuable alkaloid due to its fewer side effects and higher physiological activity. Anisodamine (6beta-hydroxyHyoscyamine) is the intermediate in the conversion of Hyoscyamine into scopolamine. Current studies report that this alkaloid is potentially applicable in medicine. The gene that codifies for Hyoscyamine 6-beta hydroxylase, the enzyme responsible for Hyoscyamine hydroxylation and epoxidation, leading to scopolamine was isolated from Brugmansia candida.
    METHODS AND RESULTS:
    The h6hcDNA was cloned into pYES2.1 and pYES2.1/V5-His-TOPO vectors to produce an untagged and a tagged protein, respectively. The H6H enzyme was produced in Saccharomyces cerevisiae in order to obtain a biological catalyst for potential industrial applications. Protein extracts of the induced yeast were analyzed by Western blot. The expression was detected 4 h after induction and no degradation was observed during the period assayed. The tagged and the untagged proteins were able to transform Hyoscyamine, showing a functional expression of the h6hcDNA.
    CONCLUSIONS:
    The strains obtained in this work are promising and potentially applicable in biocatalytic processes.